Amydis, a biotechnology company focused on diagnostic innovation, has secured a $1.1 million Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH). The funding will support the development of a non-invasive retinal imaging test designed to detect TDP-43 protein aggregates, which are key biomarkers associated with neurodegenerative diseases like amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
Advancing Retinal Diagnostics for Neurodegeneration
The NIH funding, awarded through the National Institute of Neurological Disorders and Stroke (NINDS), provides the capital necessary for Amydis to advance its proprietary platform. The company’s diagnostic approach utilizes specialized fluorescent tracers that bind to specific protein aggregates in the retina. By using standard ophthalmic imaging equipment, clinicians can visualize these markers, potentially offering a window into brain pathology.
TDP-43 (TAR DNA-binding protein 43) is a protein that normally resides in the cell nucleus but can misfold and form toxic aggregates in the cytoplasm of neurons in patients with ALS and FTD. According to the National Institute of Neurological Disorders and Stroke, identifying these pathological changes early remains a significant challenge, as definitive diagnosis often requires invasive procedures or post-mortem tissue analysis.
Why Retinal Imaging Matters
The eye is often described as an extension of the central nervous system. Because the retina shares embryonic origins and physiological characteristics with the brain, researchers have increasingly turned to ocular imaging as a surrogate for monitoring neurodegeneration.
Amydis aims to move beyond current diagnostic limitations by providing a scalable, objective measurement. By detecting protein accumulation before the onset of advanced clinical symptoms, the company hopes to improve the success rate of clinical trials for neurodegenerative therapies. Early detection is critical for testing disease-modifying drugs, as intervention is most effective in the earliest stages of neuronal damage.
Scientific Context and Future Development
The $1.1 million award follows previous research efforts aimed at translating retinal biomarkers into clinical practice. While traditional diagnostic methods for ALS and FTD—such as cerebrospinal fluid analysis or specialized PET scans—are often costly or physically taxing for patients, retinal imaging offers a non-invasive alternative that could be integrated into routine neurological and ophthalmological care.
The current phase of development, supported by the NIH grant, will focus on refining the imaging protocols and validating the sensitivity of the fluorescent tracers. As Amydis moves forward, the company must demonstrate that these retinal findings correlate accurately with disease progression in human subjects. If successful, this diagnostic tool could streamline the screening process for patients at risk for TDP-43 proteinopathies, marking a shift toward earlier, more accessible diagnosis in neurology.
Keep reading